Zohaib Ahmed
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Zohaib Ahmed has a total of 85 co-authors. Here are the top co-authors by number of shared publications:
Abdallah Kobeissy
Division of Gastroenterology and Hepatology, University of Toledo College of Medicine and Life Sciences, Toledo, OH, USA
6 shared publicationsSyeda Faiza Arif
Dow University of Health Sciences, Karachi, Pakistan
6 shared publicationsJoyce Badal
College of Medicine and Life Sciences The University of Toledo 43614 Toledo OH
5 shared publicationsAli Nawras
Division of Gastroenterology and Hepatology, University of Toledo College of Medicine and Life Sciences, Toledo, OH, USA
4 shared publicationsMuhammad Aziz
Division of Gastroenterology and Hepatology, University of Toledo, Toledo, OH
4 shared publicationsUmair Iqbal
Division of Gastroenterology and Hepatology, WellSpan Health, York, PA, USA
4 shared publications
Latest Publications
- Open Access
- 30 September 2026
- Published byĀ The Korean Society of Gastrointestinal EndoscopyĀ inĀ Clinical Endoscopy
- Vol.Ā 59 Ā (5) , 741-753
Safety and effectiveness of endoscopic ultrasound-guided coil plus glue vs. direct endoscopic glue injection for the treatment of gastric varices: a systematic review and meta-analysis
Background/Aims: Although endoscopic glue injection is the conventional first-line treatment for gastric variceal (GV) bleeding, a large body of evidence supports the safety and effectiveness of endoscopic ultrasound (EUS)-guided coil and glue injections. We compared the safety and efficacy of these two modalities.Methods: A random-effects model was used for the pooled estimates. The outcomes of interest were the odds of technical success, GV obliteration, adverse events, rebleeding, reintervention, and pulmonary embolization (PE).Results: Eight studies involving 659 patients (EUS-guided coil+glue, n=200; endoscopic glue, n=459) were included in the meta-analysis. The rebleeding (odds ratio [OR], 0.28, 95% confidence interval [CI], 0.16ā0.51; I2=0%) and reintervention (OR, 0.28; 95% CI, 0.15ā0.52; I2=0%) rates were significantly lower in the EUS-guided coil+glue. EUS-guided coil+glue group had higher rates (OR, 4.56; 95% CI, 2.04 ā10.19; I2=30%) of GV obliteration after the first session. No difference in the odds of technical success (OR, 2.03; 95% CI, 0.50ā8.22; I2=0%), adverse events (OR, 1.19; 95% CI, 0.44ā3.20; I2=45%), abdominal pain (OR, 1.17; 95% CI, 0.36ā3.82; I2=44%) fever (OR, 1.09; 95% CI, 0.41ā2.92; I2=0%), PE (OR, 0.52; 95% CI, 0.19ā1.47; I2=0%) and all-cause mortality (OR, 0.67; 95% CI, 0.32ā1.40; I2=0%) was identified.Conclusions: EUS-guided coil and glue injections are safe and effective for the treatment of gastric varices.
- 30 September 2026
- Published byĀ The Korean Society of Gastrointestinal EndoscopyĀ inĀ Clinical Endoscopy
- Vol.Ā 59 Ā (5) , 741-753
Open AccessSafety and effectiveness of endoscopic ultrasound-guided coil plus glue vs. direct endoscopic glue injection for the treatment of gastric varices: a systematic review and meta-analysis
Background/Aims: Although endoscopic glue injection is the conventional first-line treatment for gastric variceal (GV) bleeding, a large body of evidence supports the safety and effectiveness of endoscopic ultrasound (EUS)-guided coil and glue injections. We compared the safety and efficacy of these two modalities.Methods: A random-effects model was used for the pooled estimates. The outcomes of interest were the odds of technical success, GV obliteration, adverse events, rebleeding, reintervention, and pulmonary embolization (PE).Results: Eight studies involving 659 patients (EUS-guided coil+glue, n=200; endoscopic glue, n=459) were included in the meta-analysis. The rebleeding (odds ratio [OR], 0.28, 95% confidence interval [CI], 0.16ā0.51; I2=0%) and reintervention (OR, 0.28; 95% CI, 0.15ā0.52; I2=0%) rates were significantly lower in the EUS-guided coil+glue. EUS-guided coil+glue group had higher rates (OR, 4.56; 95% CI, 2.04 ā10.19; I2=30%) of GV obliteration after the first session. No difference in the odds of technical success (OR, 2.03; 95% CI, 0.50ā8.22; I2=0%), adverse events (OR, 1.19; 95% CI, 0.44ā3.20; I2=45%), abdominal pain (OR, 1.17; 95% CI, 0.36ā3.82; I2=44%) fever (OR, 1.09; 95% CI, 0.41ā2.92; I2=0%), PE (OR, 0.52; 95% CI, 0.19ā1.47; I2=0%) and all-cause mortality (OR, 0.67; 95% CI, 0.32ā1.40; I2=0%) was identified.Conclusions: EUS-guided coil and glue injections are safe and effective for the treatment of gastric varices.
- Open Access
- 1 April 2026
- Published byĀ Elmer Press, Inc.Ā inĀ Gastroenterology Research
- Vol.Ā 19 Ā (2) , 64-73
Evaluating Glucagon-Like Peptide-1 Receptor Agonist Safety Before Upper Endoscopy: A Systematic Review and Meta-Analysis
Background: The use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) has remarkably increased in the past few years as they have demonstrated significant reduction in A1c and major cardiovascular outcomes and have led to weight loss with low risk of hypoglycemia. GLP-1 RA use has raised concerns about potential associations with increased gastric retention and adverse outcomes in upper endoscopy procedures. Methods: We conducted a comprehensive search across multiple databases to identify comparative studies evaluating the impact of GLP-1 RA exposure versus non-exposure on upper endoscopy outcomes. Studies comparing GLP-1 RAs to other medications were excluded. The primary outcome was the presence of retained gastric contents, with secondary outcomes including aspiration risk and the need for repeated esophagogastroduodenoscopy (EGD). Results: Our systematic review included 28 studies, comprising data from 212,082 individuals collected between 2015 and 2023. The meta-analysis revealed that GLP-1 RA use was associated with approximately four times higher odds of retained gastric contents compared to non-exposure (odds ratio (OR): 3.95, confidence interval (CI): 2.691ā5.815, P < 0.0001, I2: 82.71%). There were no increased odds of aspiration (OR: 1.09, CI: 0.459ā2.600, P = 0.145, I2: 91.44%) or repeated upper endoscopies (OR: 1.82, CI: 0.813ā4.085, P = 0.145, I2: 85.32%). However, GLP-1 RA use was significantly associated with increased odds of procedure cancellation (OR: 3.96, CI: 2.870ā5.563, P < 0.0001, I2: 4.19%). Conclusion: While GLP-1 RAs do not increase the risk of aspiration or necessitate repeated procedures, they are linked to a higher incidence of retained gastric contents and procedure cancellations. Further randomized controlled trials are necessary to better understand the effects of GLP-1 RAs on upper endoscopy outcomes.
- 1 April 2026
- Published byĀ Elmer Press, Inc.Ā inĀ Gastroenterology Research
- Vol.Ā 19 Ā (2) , 64-73
Open AccessEvaluating Glucagon-Like Peptide-1 Receptor Agonist Safety Before Upper Endoscopy: A Systematic Review and Meta-Analysis
Background: The use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) has remarkably increased in the past few years as they have demonstrated significant reduction in A1c and major cardiovascular outcomes and have led to weight loss with low risk of hypoglycemia. GLP-1 RA use has raised concerns about potential associations with increased gastric retention and adverse outcomes in upper endoscopy procedures. Methods: We conducted a comprehensive search across multiple databases to identify comparative studies evaluating the impact of GLP-1 RA exposure versus non-exposure on upper endoscopy outcomes. Studies comparing GLP-1 RAs to other medications were excluded. The primary outcome was the presence of retained gastric contents, with secondary outcomes including aspiration risk and the need for repeated esophagogastroduodenoscopy (EGD). Results: Our systematic review included 28 studies, comprising data from 212,082 individuals collected between 2015 and 2023. The meta-analysis revealed that GLP-1 RA use was associated with approximately four times higher odds of retained gastric contents compared to non-exposure (odds ratio (OR): 3.95, confidence interval (CI): 2.691ā5.815, P < 0.0001, I2: 82.71%). There were no increased odds of aspiration (OR: 1.09, CI: 0.459ā2.600, P = 0.145, I2: 91.44%) or repeated upper endoscopies (OR: 1.82, CI: 0.813ā4.085, P = 0.145, I2: 85.32%). However, GLP-1 RA use was significantly associated with increased odds of procedure cancellation (OR: 3.96, CI: 2.870ā5.563, P < 0.0001, I2: 4.19%). Conclusion: While GLP-1 RAs do not increase the risk of aspiration or necessitate repeated procedures, they are linked to a higher incidence of retained gastric contents and procedure cancellations. Further randomized controlled trials are necessary to better understand the effects of GLP-1 RAs on upper endoscopy outcomes.
- Open Access
- 30 June 2025
- Published byĀ University of ToledoĀ inĀ Translation: The University of Toledo Journal of Medical Sciences
- Vol.Ā 13 Ā (S3)
Non-Germinal Center Diffuse Large B-Cell Lymphoma of the Liver in a Renal Transplant Patient: A Case Report
Translation: The University of Toledo Journal of Medical Sciences is the online journal launched by the University of Toledo. Manuscripts will be considered on the understanding that they report original work and are not under consideration for publication by any other journal. The journal publishes original articles reporting experimental results of basic or clinical research, case reports, and reviews. The journal uses a single blind peer review system and each manuscript, based on the results presented in its original submission, will be evaluated by two student reviewers and one faculty reviewer. This process will provide an opportunity for medical students, graduate students, residents, fellows and faculty to publish research observation in a timely manner.
- 30 June 2025
- Published byĀ University of ToledoĀ inĀ Translation: The University of Toledo Journal of Medical Sciences
- Vol.Ā 13 Ā (S3)
Open AccessNon-Germinal Center Diffuse Large B-Cell Lymphoma of the Liver in a Renal Transplant Patient: A Case Report
Translation: The University of Toledo Journal of Medical Sciences is the online journal launched by the University of Toledo. Manuscripts will be considered on the understanding that they report original work and are not under consideration for publication by any other journal. The journal publishes original articles reporting experimental results of basic or clinical research, case reports, and reviews. The journal uses a single blind peer review system and each manuscript, based on the results presented in its original submission, will be evaluated by two student reviewers and one faculty reviewer. This process will provide an opportunity for medical students, graduate students, residents, fellows and faculty to publish research observation in a timely manner.
- Open Access
- 15 December 2023
- Published byĀ University of ToledoĀ inĀ Translation: The University of Toledo Journal of Medical Sciences
- Vol.Ā 11 Ā (3)
Fecal microbiota transplant is associated with lower risk of mortality, hepatic encephalopathy, ascites, and infection patients with severe alcohol-associated hepatitis: A systematic review and meta-analysis
Translation: The University of Toledo Journal of Medical Sciences is the online journal launched by the University of Toledo. Manuscripts will be considered on the understanding that they report original work and are not under consideration for publication by any other journal. The journal publishes original articles reporting experimental results of basic or clinical research, case reports, and reviews. The journal uses a single blind peer review system and each manuscript, based on the results presented in its original submission, will be evaluated by two student reviewers and one faculty reviewer. This process will provide an opportunity for medical students, graduate students, residents, fellows and faculty to publish research observation in a timely manner.
- 15 December 2023
- Published byĀ University of ToledoĀ inĀ Translation: The University of Toledo Journal of Medical Sciences
- Vol.Ā 11 Ā (3)
Open AccessFecal microbiota transplant is associated with lower risk of mortality, hepatic encephalopathy, ascites, and infection patients with severe alcohol-associated hepatitis: A systematic review and meta-analysis
Translation: The University of Toledo Journal of Medical Sciences is the online journal launched by the University of Toledo. Manuscripts will be considered on the understanding that they report original work and are not under consideration for publication by any other journal. The journal publishes original articles reporting experimental results of basic or clinical research, case reports, and reviews. The journal uses a single blind peer review system and each manuscript, based on the results presented in its original submission, will be evaluated by two student reviewers and one faculty reviewer. This process will provide an opportunity for medical students, graduate students, residents, fellows and faculty to publish research observation in a timely manner.
- Open Access
- 5 September 2023
- Published byĀ Wolters Kluwer HealthĀ inĀ Annals of Medicine & Surgery
- Vol.Ā 85 Ā (10) , 5001-5010
Continuous vs. intermittent terlipressin infusion for portal hypertension: a systematic review and meta-analysis
Background: Portal hypertension, a major complication of chronic liver disease, often leads to life-threatening variceal bleeding, managed effectively with vasoactive drugs like terlipressin. However, the most optimal method of terlipressin administration, continuous versus intermittent infusion, remains a subject of debate, necessitating this systematic review and meta-analysis for evidence-based decision-making in managing this critical condition. Methods: This systematic review and meta-analysis adhered to the PRISMA standards and explored multiple databases until 6 April 2023, such as MEDLINE through PubMed, Scopus, Web of Science, and CENTRAL. Independent reviewers selected randomized controlled trials (RCTs) that met specific inclusion criteria. After assessing study quality and extracting necessary data, statistical analysis was performed using Review Manager (RevMan), with results presented as risk ratios (RR) or mean differences. Results: Five RCTs (n=395 patients) were included. The continuous terlipressin group had a significantly lower risk of rebleeding (RR=0.43, P=0.0004) and treatment failure (RR=0.22, P=0.02) and fewer total adverse effects (RR=0.52, PP=0.26), length of hospital stays (P=0.78), and mortality rates (P=0.65). Conclusion: This study provides robust evidence suggesting that continuous terlipressin infusion may be superior to intermittent infusions in reducing the risk of rebleeding, treatment failure, and adverse effects in patients with portal hypertension. However, further large-scale, high-quality RCTs are required to confirm these findings and to investigate the potential benefits of continuous terlipressin infusion on mortality and hospital stays.
- 5 September 2023
- Published byĀ Wolters Kluwer HealthĀ inĀ Annals of Medicine & Surgery
- Vol.Ā 85 Ā (10) , 5001-5010
Open AccessContinuous vs. intermittent terlipressin infusion for portal hypertension: a systematic review and meta-analysis
Background: Portal hypertension, a major complication of chronic liver disease, often leads to life-threatening variceal bleeding, managed effectively with vasoactive drugs like terlipressin. However, the most optimal method of terlipressin administration, continuous versus intermittent infusion, remains a subject of debate, necessitating this systematic review and meta-analysis for evidence-based decision-making in managing this critical condition. Methods: This systematic review and meta-analysis adhered to the PRISMA standards and explored multiple databases until 6 April 2023, such as MEDLINE through PubMed, Scopus, Web of Science, and CENTRAL. Independent reviewers selected randomized controlled trials (RCTs) that met specific inclusion criteria. After assessing study quality and extracting necessary data, statistical analysis was performed using Review Manager (RevMan), with results presented as risk ratios (RR) or mean differences. Results: Five RCTs (n=395 patients) were included. The continuous terlipressin group had a significantly lower risk of rebleeding (RR=0.43, P=0.0004) and treatment failure (RR=0.22, P=0.02) and fewer total adverse effects (RR=0.52, PP=0.26), length of hospital stays (P=0.78), and mortality rates (P=0.65). Conclusion: This study provides robust evidence suggesting that continuous terlipressin infusion may be superior to intermittent infusions in reducing the risk of rebleeding, treatment failure, and adverse effects in patients with portal hypertension. However, further large-scale, high-quality RCTs are required to confirm these findings and to investigate the potential benefits of continuous terlipressin infusion on mortality and hospital stays.
- Open Access
- 1 April 2023
- Published byĀ Elmer Press, Inc.Ā inĀ Gastroenterology Research
- Vol.Ā 16 Ā (2) , 79-91
Outcomes and Complications of Radiological Gastrostomy vs. Percutaneous Endoscopic Gastrostomy for Enteral Feeding: An Updated Systematic Review and Meta-Analysis
Outcomes and Complications of Radiological Gastrostomy vs. Percutaneous Endoscopic Gastrostomy for Enteral Feeding: An Updated Systematic Review and Meta-Analysis
- 1 April 2023
- Published byĀ Elmer Press, Inc.Ā inĀ Gastroenterology Research
- Vol.Ā 16 Ā (2) , 79-91
Open AccessOutcomes and Complications of Radiological Gastrostomy vs. Percutaneous Endoscopic Gastrostomy for Enteral Feeding: An Updated Systematic Review and Meta-Analysis
Outcomes and Complications of Radiological Gastrostomy vs. Percutaneous Endoscopic Gastrostomy for Enteral Feeding: An Updated Systematic Review and Meta-Analysis
- Open Access
- 1 April 2023
- Published byĀ Romanian Society of Gastroenterology and HepatologyĀ inĀ Journal of Gastrointestinal and Liver Diseases
- Vol.Ā 32 Ā (1) , 70-76
Comparative Efficacy of Treatment Options for the Prevention of Post-TIPS Hepatic Encephalopathy: A Systematic Review and Network Meta-analysis
Background and Aims: Transjugular intrahepatic portosystemic shunt (TIPS) is often used in patients with cirrhosis to manage portal hypertension-related complications. Unfortunately, 35-50% of patients develop overt hepatic encephalopathy (HE) after TIPS. However, data on lactulose and rifaximin to prevent post-TIPS HE is limited. Therefore, we aimed to perform a network meta-analysis to investigate the efficacy of multiple pharmacological regimens in the prevention of post-TIPS HE. Methods: A comprehensive search strategy to identify reports of studies of rifaximin use on post-TIPS hepatic encephalopathy was constructed using truncated keywords, phrases, and subject headings developed in Embase. This strategy was translated to MEDLINE, Cochrane Central Register of Controlled Trials, and the Web of Science Core Collection, with all searches performed on 10 February 2022. No publication date or language limits were used. Results: The initial search identified 72 studies, and 56 studies were screened after removing duplicates. Five studies, two randomized controlled trials (RCTs) and three retrospective studies, met our inclusion criteria and were included in the final analysis. A total of 840 patients were included, with 65% male. Our meta- analysis did not find a statistically significant difference between lactulose vs placebo/no prophylaxis, nor rifaximin vs placebo/no prophylaxis, nor rifaximin plus lactulose vs placebo/no prophylaxis in the reduction of post-TIPS HE. Conclusions: Rifaximin alone, lactulose alone, and rifaximin plus lactulose did not significantly reduce the development of post-TIPS HE. Based on the P-scores of the three treatment groups, the combination of rifaximin plus lactulose showed the most promising trend towards preventing post-TIPS HE. More studies, especially large RCTs, are warranted.
- 1 April 2023
- Published byĀ Romanian Society of Gastroenterology and HepatologyĀ inĀ Journal of Gastrointestinal and Liver Diseases
- Vol.Ā 32 Ā (1) , 70-76
Open AccessComparative Efficacy of Treatment Options for the Prevention of Post-TIPS Hepatic Encephalopathy: A Systematic Review and Network Meta-analysis
Background and Aims: Transjugular intrahepatic portosystemic shunt (TIPS) is often used in patients with cirrhosis to manage portal hypertension-related complications. Unfortunately, 35-50% of patients develop overt hepatic encephalopathy (HE) after TIPS. However, data on lactulose and rifaximin to prevent post-TIPS HE is limited. Therefore, we aimed to perform a network meta-analysis to investigate the efficacy of multiple pharmacological regimens in the prevention of post-TIPS HE. Methods: A comprehensive search strategy to identify reports of studies of rifaximin use on post-TIPS hepatic encephalopathy was constructed using truncated keywords, phrases, and subject headings developed in Embase. This strategy was translated to MEDLINE, Cochrane Central Register of Controlled Trials, and the Web of Science Core Collection, with all searches performed on 10 February 2022. No publication date or language limits were used. Results: The initial search identified 72 studies, and 56 studies were screened after removing duplicates. Five studies, two randomized controlled trials (RCTs) and three retrospective studies, met our inclusion criteria and were included in the final analysis. A total of 840 patients were included, with 65% male. Our meta- analysis did not find a statistically significant difference between lactulose vs placebo/no prophylaxis, nor rifaximin vs placebo/no prophylaxis, nor rifaximin plus lactulose vs placebo/no prophylaxis in the reduction of post-TIPS HE. Conclusions: Rifaximin alone, lactulose alone, and rifaximin plus lactulose did not significantly reduce the development of post-TIPS HE. Based on the P-scores of the three treatment groups, the combination of rifaximin plus lactulose showed the most promising trend towards preventing post-TIPS HE. More studies, especially large RCTs, are warranted.
- 23 March 2023
- Published byĀ WileyĀ inĀ Journal of Gastroenterology and Hepatology
- Vol.Ā 38 Ā (5) , 703-709
Role of rifaximin in the management of alcoholāassociated hepatitis: A systematic review and metaāanalysis
Background and AimAlcohol-associated hepatitis (AAH) is an acute, inflammatory liver disease with severe short-term and long-term morbidity and mortality. AAH can lead to severe complications including hepatic failure, gastrointestinal bleeding, sepsis, and the development or decompensation of cirrhosis. Rifaximin is an antibiotic that reduces bacterial overgrowth and gut translocation, and it may have a role in decreasing systemic inflammation and infection in patients with AAH. Therefore, we conducted a systematic review and meta-analysis to evaluate the role of rifaximin in the management of AAH. MethodsA comprehensive search strategy was used to identify studies that met our inclusion criteria in Embase, MEDLINE (PubMed), Cochrane Library, Web of Science Core Collection, and Google Scholar. Outcomes of interest included rates of infection, 90-day mortality, and overall mortality between the rifaximin versus non-rifaximin group. Open Meta Analyst software was used to compute the results. ResultsThree studies with a total of 162 patients were included in the final meta-analysis. Of the three studies, two were randomized control trials (RCTs), and one was a case-control study. There was a significantly lower rate of infection in the rifaximin group versus the non-rifaximin group (RR: 0.331, 95% CI: 0.159-0.689, I-2 = 0%, P = 0.003). There was no significant difference in 90-day mortality in the rifaximin versus non-rifaximin group (RR: 0.743, 95% CI: 0.298-1.850, I-2 = 24%, P = 0.523), nor was there a significant difference in overall mortality (RR: 0.624, 95% 95% CI: 0.299-1.3, I-2 = 7.1%, P = 0.208). ConclusionsThe use of rifaximin in AAH is associated with a lower rate of infection rate than the non-rifaximin group. Additional research is needed to determine whether this effect is more pronounced in patients concurrently being treated with prednisolone. Differences in 90-day or overall mortality did not reach statistical significance. Further studies, particularly large randomized controlled trials, are needed to establish the role of rifaximin in AAH, especially as an adjunct therapy with prednisolone.
- 23 March 2023
- Published byĀ WileyĀ inĀ Journal of Gastroenterology and Hepatology
- Vol.Ā 38 Ā (5) , 703-709
Role of rifaximin in the management of alcoholāassociated hepatitis: A systematic review and metaāanalysis
Background and AimAlcohol-associated hepatitis (AAH) is an acute, inflammatory liver disease with severe short-term and long-term morbidity and mortality. AAH can lead to severe complications including hepatic failure, gastrointestinal bleeding, sepsis, and the development or decompensation of cirrhosis. Rifaximin is an antibiotic that reduces bacterial overgrowth and gut translocation, and it may have a role in decreasing systemic inflammation and infection in patients with AAH. Therefore, we conducted a systematic review and meta-analysis to evaluate the role of rifaximin in the management of AAH. MethodsA comprehensive search strategy was used to identify studies that met our inclusion criteria in Embase, MEDLINE (PubMed), Cochrane Library, Web of Science Core Collection, and Google Scholar. Outcomes of interest included rates of infection, 90-day mortality, and overall mortality between the rifaximin versus non-rifaximin group. Open Meta Analyst software was used to compute the results. ResultsThree studies with a total of 162 patients were included in the final meta-analysis. Of the three studies, two were randomized control trials (RCTs), and one was a case-control study. There was a significantly lower rate of infection in the rifaximin group versus the non-rifaximin group (RR: 0.331, 95% CI: 0.159-0.689, I-2 = 0%, P = 0.003). There was no significant difference in 90-day mortality in the rifaximin versus non-rifaximin group (RR: 0.743, 95% CI: 0.298-1.850, I-2 = 24%, P = 0.523), nor was there a significant difference in overall mortality (RR: 0.624, 95% 95% CI: 0.299-1.3, I-2 = 7.1%, P = 0.208). ConclusionsThe use of rifaximin in AAH is associated with a lower rate of infection rate than the non-rifaximin group. Additional research is needed to determine whether this effect is more pronounced in patients concurrently being treated with prednisolone. Differences in 90-day or overall mortality did not reach statistical significance. Further studies, particularly large randomized controlled trials, are needed to establish the role of rifaximin in AAH, especially as an adjunct therapy with prednisolone.
- Open Access
- 1 December 2022
- Published byĀ Elmer Press, Inc.Ā inĀ Gastroenterology Research
- Vol.Ā 15 Ā (6) , 325-333
Transjugular Intrahepatic Portosystemic Shunt Outcomes in the Elderly Population: A Systematic Review and Meta-Analysis
Transjugular Intrahepatic Portosystemic Shunt Outcomes in the Elderly Population: A Systematic Review and Meta-Analysis
- 1 December 2022
- Published byĀ Elmer Press, Inc.Ā inĀ Gastroenterology Research
- Vol.Ā 15 Ā (6) , 325-333
Open AccessTransjugular Intrahepatic Portosystemic Shunt Outcomes in the Elderly Population: A Systematic Review and Meta-Analysis
Transjugular Intrahepatic Portosystemic Shunt Outcomes in the Elderly Population: A Systematic Review and Meta-Analysis
- 9 November 2022
- Published byĀ Springer NatureĀ inĀ Digestive Diseases and Sciences
- Vol.Ā 68 Ā (4) , 1411-1425
Cap-Assisted Endoscopic Esophageal Foreign Body Removal Is Safe and Efficacious Compared to Conventional Methods
Introduction Esophageal foreign body impaction (FBI) is a commonly encountered gastrointestinal emergency requiring immediate intervention. Foreign bodies can be composed of food, commonly referred to as a "food bolus" (FB), or other matter (non-food). We aim to conduct systematic review and meta-analysis to compare cap-assisted and conventional endoscopic techniques for removal of esophageal FBI. Methods A comprehensive search technique was utilized to identify studies that used capped endoscopic devices to remove FB or other esophageal foreign bodies. The primary outcomes were the technical success rate, rate of en bloc retrieval, and procedure time. Secondary outcomes were overall adverse events, bleeding, mucosal tears, and perforation. Results Seven studies with a total of 1407 patients were included. The mean patient age was 55.3 (SD ± 7.2) years and 44.8% of patients were male. There were two RCTs and five observational studies among the included studies. The technical success rate was significantly higher in the cap-assisted group compared to the conventional group (OR 3.47, CI 1.68ā7.168, I2 = 0%, p = < 0.001), as well as the en bloc retrieval rate (OR 26.90, CI 17.82ā40.60, I2 = 0%, p = 0.001). There was a trend towards lower procedural time for the cap-assisted group compared to the conventional group, although the difference did not reach statistical significance (MD ā 10.997, CI ā 22.78ā0.786, I2 = 99.9%, p = 0.06). The overall adverse events were significantly lower in the cap-assisted group compared to the conventional group (OR 0.118, CI 0.018ā0.792, I2 = 81.79%, p = 0.02). Conclusion The cap-assisted technique has improved efficacy and safety. To confirm these results, larger randomized trials are warranted.
- 9 November 2022
- Published byĀ Springer NatureĀ inĀ Digestive Diseases and Sciences
- Vol.Ā 68 Ā (4) , 1411-1425
Cap-Assisted Endoscopic Esophageal Foreign Body Removal Is Safe and Efficacious Compared to Conventional Methods
Introduction Esophageal foreign body impaction (FBI) is a commonly encountered gastrointestinal emergency requiring immediate intervention. Foreign bodies can be composed of food, commonly referred to as a "food bolus" (FB), or other matter (non-food). We aim to conduct systematic review and meta-analysis to compare cap-assisted and conventional endoscopic techniques for removal of esophageal FBI. Methods A comprehensive search technique was utilized to identify studies that used capped endoscopic devices to remove FB or other esophageal foreign bodies. The primary outcomes were the technical success rate, rate of en bloc retrieval, and procedure time. Secondary outcomes were overall adverse events, bleeding, mucosal tears, and perforation. Results Seven studies with a total of 1407 patients were included. The mean patient age was 55.3 (SD ± 7.2) years and 44.8% of patients were male. There were two RCTs and five observational studies among the included studies. The technical success rate was significantly higher in the cap-assisted group compared to the conventional group (OR 3.47, CI 1.68ā7.168, I2 = 0%, p = < 0.001), as well as the en bloc retrieval rate (OR 26.90, CI 17.82ā40.60, I2 = 0%, p = 0.001). There was a trend towards lower procedural time for the cap-assisted group compared to the conventional group, although the difference did not reach statistical significance (MD ā 10.997, CI ā 22.78ā0.786, I2 = 99.9%, p = 0.06). The overall adverse events were significantly lower in the cap-assisted group compared to the conventional group (OR 0.118, CI 0.018ā0.792, I2 = 81.79%, p = 0.02). Conclusion The cap-assisted technique has improved efficacy and safety. To confirm these results, larger randomized trials are warranted.